Myogen (NASDAQ:MYOG)
Historical Stock Chart
From May 2019 to May 2024
Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on the
discovery, development and commercialization of small molecule
therapeutics for the treatment of cardiovascular disorders, today
announced that an abstract describing the effects of darusentan on
resistant hypertension (RHTN) has been selected for presentation at the
International Society of Hypertension (ISH) to be held Oct. 15-19, 2006,
in Fukuoka, Japan.
Lars Lindholm, M.D., will lead the six-minute moderated poster
presentation based on the abstract titled “Darusentan
for Resistant Hypertension.” The presentation
is scheduled for Wednesday, Oct. 18, 2006, at 1:35 p.m. at the Marine
Messe Fukuoka, 7-1 Okihama-machi, Hakata-ku, Fukuoka. Dr. Lindholm is a
professor at the Umea University Hospital in Sweden and a member of the
clinical advisory group for the darusentan development program.
Myogen has two product candidates in late-stage clinical development:
ambrisentan for the treatment of patients with pulmonary arterial
hypertension (PAH) and darusentan for the treatment of patients with
resistant hypertension. Myogen and GlaxoSmithKline have entered into a
global PAH collaboration in which Myogen has marketing and distribution
rights to GlaxoSmithKline's Flolan®
(epoprostenol sodium) for Injection in the United States and
GlaxoSmithKline has licensed ambrisentan from Myogen for all territories
outside of the United States, where Myogen retains exclusive rights.
Myogen also conducts a target and drug discovery research program
focused on the development of disease-modifying drugs for the treatment
of chronic heart failure and related cardiovascular disorders. Please
visit Myogen's website at www.myogen.com.
Safe Harbor Statement
The anticipated presentation will contain forward-looking statements
that involve significant risks and uncertainties, including those to be
discussed in the presentation and others that can be found in the “Risk
Factors” section of Myogen’s
Form 10-K for the year ended December 31, 2005 and Myogen’s
periodic reports on Form 10-Q and Form 8-K. Myogen does not undertake
any obligation to update any forward-looking statements contained in the
anticipated presentation as a result of new information, future events
or otherwise. The company cautions investors not to place undue reliance
on the forward-looking statements contained in this press release or the
presentation. No forward-looking statement can be guaranteed and actual
events and results may differ materially from those projected.
Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused
on the discovery, development and commercialization of small molecule
therapeutics for the treatment of cardiovascular disorders, today
announced that an abstract describing the effects of darusentan on
resistant hypertension (RHTN) has been selected for presentation at
the International Society of Hypertension (ISH) to be held Oct. 15-19,
2006, in Fukuoka, Japan.
Lars Lindholm, M.D., will lead the six-minute moderated poster
presentation based on the abstract titled "Darusentan for Resistant
Hypertension." The presentation is scheduled for Wednesday, Oct. 18,
2006, at 1:35 p.m. at the Marine Messe Fukuoka, 7-1 Okihama-machi,
Hakata-ku, Fukuoka. Dr. Lindholm is a professor at the Umea University
Hospital in Sweden and a member of the clinical advisory group for the
darusentan development program.
Myogen has two product candidates in late-stage clinical
development: ambrisentan for the treatment of patients with pulmonary
arterial hypertension (PAH) and darusentan for the treatment of
patients with resistant hypertension. Myogen and GlaxoSmithKline have
entered into a global PAH collaboration in which Myogen has marketing
and distribution rights to GlaxoSmithKline's Flolan(R) (epoprostenol
sodium) for Injection in the United States and GlaxoSmithKline has
licensed ambrisentan from Myogen for all territories outside of the
United States, where Myogen retains exclusive rights. Myogen also
conducts a target and drug discovery research program focused on the
development of disease-modifying drugs for the treatment of chronic
heart failure and related cardiovascular disorders. Please visit
Myogen's website at www.myogen.com.
Safe Harbor Statement
The anticipated presentation will contain forward-looking
statements that involve significant risks and uncertainties, including
those to be discussed in the presentation and others that can be found
in the "Risk Factors" section of Myogen's Form 10-K for the year ended
December 31, 2005 and Myogen's periodic reports on Form 10-Q and Form
8-K. Myogen does not undertake any obligation to update any
forward-looking statements contained in the anticipated presentation
as a result of new information, future events or otherwise. The
company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release or the
presentation. No forward-looking statement can be guaranteed and
actual events and results may differ materially from those projected.